

Special Issue

The Role of Natural Products on Diabetes Mellitus Treatment, 2nd Edition

Message from the Guest Editors

Diabetes mellitus (DM) is a metabolic disease characterized by hyperglycemia due to the secretion and/or action of insulin. Metformin (a biguanide), which is a derivative of galegin, is among the first-line therapies for the treatment of type II DM. This guanidine was isolated from *Galega officinalis* L., a plant that has been used since the Middle Ages by diabetic patients. This fact has aroused interest in the use of medicinal plants and their secondary metabolites as possible drugs in DM treatment. Although it is difficult to find a substitute for insulin among plants, it is possible that molecules can be found that stimulate endogenous insulin biosynthesis and secretion or increase glucose absorption in blood by peripheral tissues, by acting as insulinomimetic or insulin secretagogic agents. Following on from the above, this second edition of the Special Issue is focused on the study of natural products (characterized extracts and isolated secondary metabolites) in the treatment of diabetes mellitus complications by in vivo and in vitro assays. Clinical trials are also welcome.

Guest Editors

Prof. Dr. Diana Marcela Aragon Novoa

Departamento de Farmácia, Facultad de Ciencias, Universidad Nacional de Colombia, Cra. 30 45-03, Bogotá 111321, DC, Colombia

Prof. Dr. Fátima Regina Mena Barreto Silva

1. Laboratory of Hormones & Signal Transduction, Department of Biochemistry, Center of Biological Sciences, Campus Trindade, Federal University of Santa Catarina, Florianópolis 88040-900, SC, Brazil

2. Laboratory of Biochemistry and Pharmacology, Department of Pharmacology and Physiology, Drug Research and Development Center (DRDC), Medical School, Federal University of Ceará, Rua Coronel Nunes de Melo, Fortaleza 60430-275, CE, Brazil

Deadline for manuscript submissions

closed (30 June 2023)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/155303

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).